Cholesstrinol Formulas

Product Description:
Cholesstrinol™ is an award winning platform of proprietary heart healthy formulas that tells a powerful brand story. It pulls together the detailed scientific data in an easy-to-understand package for the consumer reducing, if not eliminating, the need for laborious guesswork or research on their part. Branding these combinations under one name – Cholesstrinol™ – is designed to leverage their scientific basis. It is a widely scoped and all-encompassing platform that provides numerous targeted and customized solutions for consumers with specific cardiovascular concerns.

Cholesstrinol includes a range of ingredients for multiple heart healthy solutions:** The FDA has concluded that products containing at least 0.4g of free plant sterol eaten twice a day with meals for a daily total intake of at least 0.8g as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. Clinical studies show that sterols lower LDL cholesterol by blocking the absorption of cholesterol into the body.

* FDA approved health claim: Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 essential fatty acids may reduce the risk of coronary heart disease.

Market Opportunity:
Approximately 64 million Americans suffer from cardiovascular complications, which are increasingly being observed in younger age groups, including adolescents. Consequently it is no surprise that consumers are becoming increasingly concerned about heart disease and its risk factors, including the role of high blood cholesterol levels, which cause about a third of all cases of all cardiovascular disease, resulting in nearly 17 million deaths annually. Such increased consumer awareness coupled with valid concerns about prescription drugs has driven demand for natural heart-health products.

Statin drugs, a conventional treatment for high cholesterol, are often expensive and can have complications including depleting the body’s natural ability to produce CoQ10.

Statin drugs block the human bodies natural production of Coenzyme Q10 (Coenzyme Q10 production shares the same metabolic pathway that is effected by statins which are the #1 selling prescription drug in the world).

Many people don’t realize or understand that red yeast rice blocks this same pathway and is almost identical to prescription statins in chemical structure.

Adding to consumer safety concerns Consumer Labs reported that 40% of Red Yeast Rice products tested in the U.S. contained toxic citrinin, and the amount of lovastatin (statin drug) in each product varied more than 100-fold. A UCLA study supports the Consumer Labs findings as it showed that only one of nine Red Yeast Rice supplements bought in health food stores contained all the monacolins that lower cholesterol, and seven of nine Red Yeast Rice supplements contained measurable concentrations of toxic citrinin. Canada has banned Red Yeast Rice. In the U.S., the FDA has taken the position that “red yeast rice products containing standardized lovastatin levels are unapproved new drugs.”

Clearly, Red Yeast Rice has been, and continues to be, under heavy regulatory scrutiny and safety concerns persist. Increasingly, consumers are demanding natural, clinically viable, science-based heart healthy options. Now there is a family of formulas that provides numerous targeted and customized science-based natural solutions. SourceOne can provide an excellent heart healthy solution with the introduction of the award winning Cholesstrinol family of heart healthy formulas.

Natural foods and nutritional supplements can play a significant role and are increasingly being sought by consumers. The more support we provide our bodies, the more they can function effectively, and the greater the possibility of achieving balanced systems and overall health and wellness.

Many factors such as diet, exercise, body weight and age can affect your cholesterol levels. That’s why doctors recommend a diet low in saturated fat and regular exercise as a part of a cholesterol management program. However, diet and exercise alone don’t always reduce your cholesterol levels to the desired range.

Innovation:

SouceOne is a leader in introducing new innovations and scientific technologies that help deliver health and wellness through natural products. We are relentless in our pursuit of quality and improvements in nutritional supplements, functional foods and beverages, cosmetics, and animal nutrition that offer more and better solutions to the growing need for healthy and nutritious wellness options. Our dedicated team of global research partners invests heavily in research and development (R&D) and scientific studies. They also work closely with major universities, medical institutions, and clinical research organizations (CROs) to further ensure we have the newest developments keeping SourceOne on the cutting edge of the latest scientific discoveries.

SourceOne has partnered exclusively with Vesifact to use its advanced technologies to enhance the health benefits absorption and bioavailability. Marc Weder, co-founder and CEO suggested, “Using Vesifact’s patented natural association colloid system, we can improve these unique science-based ingredients and proprietary Cholesstrinol formulas, and meet the growing demand for enhanced bioavailability by taking the absorption and efficacy to the next level.”

Vesifact and SourceOne currently have multiple studies underway with several more planned throughout 2009 that will provide additional scientific support for the proprietary formulas in the Cholesstrinol family.

Solutions:

Cholesstrinol is a first in the industry, as it represents natural and innovative solutions for heath conscious consumers to efficiently, safely, and scientifically address customized formulas for a wide range of heart health concerns.

SourceOne is the recipient of the 2008 Frost & Sullivan Award for Product Innovation of the Year in the U.S. Heart Health Supplements Market for our Cholesstrinol family of heart healthy formulas. As the award states, the key factors leading to the success of Cholesstrinol are:

Understanding Consumer Concerns
Strong Science
Effective Marketing Campaign
Strategic Alliances

Please click here for the full award description.

Clinical Science:

Every product under the Cholesstrinol™ umbrella is supported by a strong platform of clinical evidence demonstrating conclusive ability to deliver a desirable range of heart-healthy benefits. These attributes may include significantly improving healthy total cholesterol and triglyceride levels, as well as healthy LDL, VLDL, and HDL cholesterol levels, providing powerful antioxidant effects, promoting the body’s natural anti-inflammatory response, and supporting healthy blood pressure and glucose levels. In addition, Cholesstrinol ™ significantly reduces many of the key biomarkers associated with metabolic syndrome.

The benefits of the ingredients in the Cholesstrinol™ family of formulas have been validated in hundreds of clinical studies. The fact is, there are thousands of studies supporting the many health benefits of both marine Omega-3 EFAs and soy based phytosterols. Some products claim to be “clinically proven”; however, the ingredients used in the trial are not available to the consumer. Furthermore, too often the effective dose used in the clinical trials is not the same dosage found in supplements on retail shelves. SourceOne provides a consistent and reliable supply of the science-based ingredients that make up our Cholesstrinol™ family of formulas – the same ingredients at the same effective dose used in the clinical trials.

Also, in Alternative Therapies in Health and Medicine, November/December, 2007, Vol. 13, No. 6, results were published of several studies that combined TocoSource® Palm Tocotrienols and PMF-source™ Citrus Flavonoids in Cholesstrinol The largest study of the group, a 12-week double-blind, placebo-controlled protocol with 120 subjects, resulted in significant improvements in total cholesterol (-30%), LDL (-27%), and triglycerides (-34%), compared to placebo. In addition, HDL levels increased 4%, resulting in a significant 29% improvement in the LDL:HDL ratio.

Please click here for the full study.

References:

Roza, et al. Effect of Citrus Flavonoids and Tocotrienols on Serum Cholesterol Levels in Hypercholesterolemic Subjects (Cholesstrinol™) Alternative Therapies in Health & Medicine 13(6) 2007, 44–48.
American Heart Association. What Your Cholesterol Levels Mean. Available at: American Heart Association. Accessed August 24, 2007.
Your Guide to Lowering Your Cholesterol With TLC. Washington, DC: US Dept of Health and Human Services; 2005. NIH publication 06-5235.
Cook NC, Samman S. Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem. 1996;7(2):66-76.
Borradaile NM, Carroll KK, Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus fl avanones hesperetin and naringenin. Lipids. 1999;34(6):591-598.
Kurowska EM, Manthey JA, Hasegawa S, Manners GD, Vandenberg TA. Cholesterollowering effects of citrus juices, flavonoids and limonoids. Paper presented at: International Conference and Exhibition on Nutraceuticals and Functional Foods; September 13-17, 2000; Houston, TX.
Kurowska EM, Banh C, Hasegawa S, Manners GD. Regulation of Apo B production in HepG2 cells by citrus limonoids. In: Berhow MA, Hasegawa S, eds. Citrus Limonoids: Functional Chemicals in Agriculture and Foods. ACS Symposium Series. Washington, CD: American Chemical Society; 2000:175-184.
Kurowska EM, Borradaile NM. Hypocholesterolemic effects of dietary citrus juices in rabbits. Nutr Res. 2000;20:121-129.
Kurowska EM, Spence JD, Jordan J, et al. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr. 2000;72(5):1095-1100.
Manthey JA, Guthrie N, Grohmann K. Biological properties of citrus fl avonoids pertaining to cancer and infl ammation. Curr Med Chem. 2000;8(2):135-153.
Kumamoto H, Matsubara Y, Iizuka Y, Okamoto K, Yokoi K. Structure and hypotensive effect of fl avonoid glycosides in orange (Citrus sinensis OSBECK) peelings. Agric Biol Chem. 1986;50(3):781-783.
Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc. 2000;75(4):369-380.
Lemos VS, Freitas MR, Muller B, Lino YD, Queiroga CE, Côrtes SF. Dioclein, a new nitric oxide-and endothelium-dependent vasodilator flavonoid. Eur J Pharmacol. 1999;386(1):41-46.
Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy- 3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268(15):11230-11238.
Guthrie N, Kurowska EM. Anti-cancer and cholesterol-lowering activities of tocotrienols. In: Wildman REC, ed. Handbook of Nutraceuticals and Functional Foods. Boca Raton, FL: CRC Press; 2000:269-280.
Black™ , Wang P, Maeda N, Coleman RA. Palm tocotrienols protect ApoE +/-mice from diet-induced atheroma formation. J Nutr. 2000;130(10):2420-2426.
Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids. 1995; 30(12):1171-1177.
Quereshi AA, Bradlow BA, Salser WA, Brace LD. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. Nutr Biochem. 1997;8(5):290-298.
Mensink RP, van Houvelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. 1999;69(2):213-219.
Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exper Hypertens. 1999;21(8):1297-1313.
Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32(5):309-319.
Smogorzewski M. The myopathy of statins. J Ren Nutr. 2005;15(1):87-93.
Silver M, Langsjoen P, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94(10):1306-1310.
Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13(2):76-79.
Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus fl avonoids pertaining to cancer and infl ammation. Curr Med Chem. 2001;8(2):135-153.
Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A. 1996;93(21):11991-11995.
Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipo-protein B lipoprotein assembly. Curr Opin Lipidol. 1997;8(3):131-137.
Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyfl avone, tangeretin. Lipids. 2004;39(2):143-151.
Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3- hydroxy- 3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268(15):11230-11238.
Pearce BC, Parker RA, Deason ME, Quereshi AA, Wright JJ. Hypercholesterolemic activity of synthetic and natural tocotrienols. J Med Chem. 1992;35(20):3595-3606.
Quereshi AA, Pearce BC, Nor RM, Gapor A, Peterson DM, Elson CE. Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on Hepatic 3-hydroxy- 3-methylglutaryl coenzyme A reductase activity in chickens. J Nutr. 1996;126(2):389-394.
Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32(5):309-319.
Kurowska EM, Laidlaw M, Barber J, et al. Sytrinol™ , a novel cholesterol-lowering supplement. Paper presented at: Canadian Federation of Biological Sciences Annual Meeting; June 21-25, 2005; Guelph, Ontario, Canada.